Sex Cord-Gonadal Stromal Tumor Market Research Report – Forecast to 2027

Sex Cord-Gonadal Stromal Tumor Market Research Report: By Type (Granulosa Cell Tumor, Sertoli Cell Tumor, Others), By Diagnosis (Microscopy, Tumor Marker, Others), By Treatment (Chemotherapy, Surgery, Others), and By End-User – Global Forecast Till 2027

ID: MRFR/MED/4456-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data

Market Scenario


The sex cord-gonadal stromal tumor is a rare type of cancer derived from the stromal component of the ovary and testis. This tumor comprises granulosa, thecal cells, and fibrocytes. Sex cord-gonadal stromal tumors are mostly of seven types, namely, granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, gynandroblastoma, Sex Cord Tumor with Annular Tubules (SCTAT), and Sertoli Leydig cell tumor. In humans, this type of tumor accounts for 8% of the ovarian cancers and around 5% of testicular cancers.


It is noted that the increasing cases of ovarian and testicular cancer, technological advancements, and increasing healthcare expenditure are the key factors driving the sex cord-gonadal stromal tumor market.


Various other factors such as the growing awareness about the cord-gonadal stromal tumor, unmet medical needs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the global sex cord-gonadal stromal tumor market.


Despite these drivers, there are some setbacks associated with the sex cord-gonadal stromal tumor market. Strict FDA regulations, a huge capital investment with low-profit margins, and poor healthcare system in low and middle-income countries may hinder the growth of the sex cord-gonadal stromal tumor market to a considerable extent.


It is estimated that the sex cord-gonadal stromal tumor market is expected to grow at a CAGR of 6.5% during the forecast period of 2017–2023.


Research Methodology


 sex cord-gonadal stromal tumor market


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience



  • Medical Device Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institutes

  • Academic Institutes and Universities


Segmentation


The global sex cord-gonadal stromal tumor market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of tumor type, the sex cord-gonadal stromal tumor market is classified as granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, Sertoli Leydig cell tumor, gynandroblastoma, and Sex Cord Tumor with Annular Tubules (SCTAT). The granulosa cell tumor is further classified as functioning tumors and non-functioning tumors.


On the basis of diagnosis, the sex cord-gonadal stromal tumor market is classified as microscopy immunohistochemistry, tumor marker, ultrasound, Magnetic Resonance Imaging (MRI), and others. The tumor marker segment is further classified as inhibin-alpha, calretinin, Melan-A, and others.


On the basis of treatment, the sex cord-gonadal stromal tumor market is classified as chemotherapy, radiotherapy, surgery, and others. The surgery segment is further classified as salpingo-oophorectomy, abdominal hysterectomy, Retroperitoneal Lymph Node Dissection (RPLND), and radical inguinal orchiectomy. The sub-segment of salpingo-oophorectomy includes unilateral salpingo-oophorectomy and bilateral salpingo-oophorectomy.


On the basis of end-user, the sex cord-gonadal stromal tumor market is segmented into hospitals and clinics, cancer research centers, research and academic institutes, and others.


Regional Analysis


The Americas dominates the sex cord-gonadal stromal tumor market owing to the increasing prevalence of ovarian cancer in this region and high healthcare expenditure. According to the American Cancer Society, around 22,240 women are likely to be diagnosed with ovarian cancer, and 14,070 women are likely to die from ovarian cancer, in 2018.


Europe holds the second position in the sex cord-gonadal stromal tumor market. The financial support provided by the government towards R&D and technological advancements are expected to drive the European sex cord-gonadal stromal tumor market. The increasing healthcare expenditure is also boosting the European sex cord-gonadal stromal tumor market.


According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014, i.e., EUR 321 billion which is further followed by France with EUR 237 billion and United Kingdom with EUR 223 billion. In the year 2016, the R&D expenditure in the pharmaceutical industry was EUR 35000 million, suggested by the European Federation of Pharmaceutical Industries and Association.


Asia Pacific is the fastest growing sex cord-gonadal stromal tumor market owing to a huge patient pool and development in the pharmaceutical sector. Healthcare expenditure is found to be boosting in various regions of Asia Pacific. As per the data suggested by the Australian Institute of Health and Welfare during the year 2015–2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014–2015.


The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the global sex cord-gonadal stromal tumor market are Abbott, Abcam plc, Affymetrix, Inc., Agilent Technologies, Inc., Beckman, Dickinson and Company (BD), Bio SB Inc., BioCurex, BioModa, Inc., Bio-Rad Laboratories, Inc., Boston Scientific Corporation, Cell Signaling Technology, Inc., Clarient, Inc., CooperSurgical Inc., Correlogic Systems, Inc., Danaher Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Gen-Probe, Inc., Hologic, Inc., Johnson & Johnson Services, Inc., Karl Storz GmbH & Co. Kg, LiNA Medical USA, Merck Millipore, PerkinElmer, Inc., Qiagen, Radient Pharmaceuticals, Thermo Fisher Scientific Inc., Veridex LLC, and others.



Frequently Asked Questions (FAQ) :


A sex cord-gonadal stromal tumor is a rare type of cancer derived from the stromal component of the ovary and testis. 

The market is expected to exhibit a strong 6.5% CAGR over the forecast period from 2017 to 2023.

The increasing prevalence of ovarian and testicular cancer is the major driver for the global market.

Americas dominate the global sex cord-gonadal stromal tumor market.

Leading players in the Sex Cord-Gonadal Stromal Tumor Market include Abbott, Bio-Rad Laboratories, and Karl Storz, among others.

Table Of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type

6.1 Introduction

6.2 Granulosa Cell Tumor

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Sertoli Cell Tumor

6.3.1 Market Estimates & Forecast, 2020–2027

6.4 Thecoma

6.4.1 Market Estimates & Forecast, 2020–2027

6.5 Leydig Cell Tumor

6.5.1 Market Estimates & Forecast, 2020–2027

6.6 Sertoli-Leydig Cell Tumor

6.6.1 Market Estimates & Forecast, 2020–2027

6.7 Gynandroblastoma

6.7.1 Market Estimates & Forecast, 2020–2027

6.8 Sex Cord Tumor With Annular Tubules (SCTAT)

6.8.1 Market Estimates & Forecast, 2020–2027

Chapter 7. Global Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis

7.1 Introduction

7.2 Microscopy

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Immunohistochemistry

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Tumor Marker

7.4.1 Market Estimates & Forecast, 2020–2027

7.5 Ultrasound

7.5.1 Market Estimates & Forecast, 2020–2027

7.6 MRI

7.6.1 Market Estimates & Forecast, 2020–2027

7.7 Others

7.7.1 Market Estimates & Forecast, 2020–2027

Chapter 8. Global Sex Cord–Gonadal Stromal Tumor Market, By Treatment

8.1 Introduction

8.2 Chemotherapy

8.2.1 Market Estimates & Forecast, 2020–2027

8.3 Radiotherapy

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Surgery

8.4.1 Market Estimates & Forecast, 2020–2027

8.5 Others

8.5.1 Market Estimates & Forecast, 2020–2027

Chapter 9. Global Sex Cord–Gonadal Stromal Tumor Market, By End-User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Cancer Research Centers

9.3.1 Market Estimates & Forecast, 2020–2027

9.4 Research And Academic Institutes

9.4.1 Market Estimates & Forecast, 2020–2027

9.5 Others

9.5.1 Market Estimates & Forecast, 2020–2027

Chapter 12. Global Sex Cord–Gonadal Stromal Tumor Market, By Region

12.1 Introduction

12.2 Americas

12.2.1 North America

12.2.1.1 U.S.

12.2.1.1 Canada

12.2.2 South America

12.3 Europe

12.3.1 Western Europe

12.3.1.1 Germany

12.3.1.2 France

12.3.1.3 Italy

12.3.1.4 Spain

12.3.1.5 U.K.

12.3.1.6 Rest Of Western Europe

12.3.2 Eastern Europe

12.4 Asia Pacific

12.4.1 Japan

12.4.2 China

12.4.3 India

12.4.4 Australia

12.4.5 Republic Of Korea

12.4.6 Rest Of Asia Pacific

12.5 The Middle East & Africa

12.5.1 United Arab Emirates

12.5.2 Saudi Arabia

12.5.3 Oman

12.5.4 Kuwait

12.5.5 Qatar

12.5.6 Rest Of The Middle East & Africa

Chapter 13 Company Landscape

13.1 Introduction

13.2 Market Share Analysis

13.3 Key Development & Strategies

13.3.1 Key Developments

Chapter 14 Company Profiles

14.1 Abbott

14.1.1 Company Overview

14.1.2 Tumor Types Overview

14.1.3 Financials

14.1.4 SWOT Analysis

14.2 Beckman, Dickinson And Company (BD)

14.2.1 Company Overview

14.2.2 Tumor Types Overview

14.2.3 Financial Overview

14.2.4 Key Developments

14.2.5 SWOT Analysis

14.3 Johnson & Johnson Services, Inc.

14.3.1 Company Overview

14.3.2 Tumor Types Overview

14.3.3 Financial Overview

14.3.4 Key Development

14.3.5 SWOT Analysis

14.4 Bio-Rad Laboratories, Inc.

14.4.1 Company Overview

14.4.2 Tumor Types/Business Segment Overview

14.4.3 Financial Overview

14.4.4 Key Development

14.4.5 SWOT Analysis

14.5 BOSTON SCIENTIFIC CORPORATION

14.5.1 Company Overview

14.5.2 Tumor Types Overview

14.5.3 Financial Overview

14.5.4 Key Developments

14.6 CooperSurgical Inc.

14.6.1 Company Overview

14.6.2 Tumor Types Overview

14.6.3 Financial Overview

14.6.4 Key Developments

14.7 DANAHER CORPORATION

14.7.1 Overview

14.7.2 Tumor Types Overview

14.7.3 Financials

14.7.4 Key Developments

14.7.5 SWOT Analysis

14.8 Others

Chapter 15 MRFR Conclusion

15.1 Key Findings

15.1.1 From CEO’s View Point

15.1.2 Unmet Needs Of The Market

15.2 Key Companies To Watch

15.3 Prediction Of The Sex Cord–Gonadal Stromal Tumor Industry

Chapter 16 Appendix

LIST OF TABLES

Table 1 Sex Cord–Gonadal Stromal Tumor Industry Synopsis, 2020–2027

Table 2 Sex Cord–Gonadal Stromal Tumor Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Sex Cord–Gonadal Stromal Tumor Market, By Region, 2020–2027, (USD Million)

Table 4 Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 5 Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 6 Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 7 Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

Table 8 North America Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 9 North America Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 10 North America Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 11 North America Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

Table 12 U.S. Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 13 U.S. Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 14 U.S. Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 15 U.S. Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

Table 16 Canada Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 17 Canada Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 18 Canada Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 19 Canada Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

Table 20 South America Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 21 South America Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 22 South America Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 23 South America Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

Table 24 Europe Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 25 Europe Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 26 Europe Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 27 Europe Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

Table 28 Western Europe Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 29 Western Europe Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 30 Western Europe Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

Table 32 Eastern Europe Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 33 Eastern Europe Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 34 Eastern Europe Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

Table 36 Asia Pacific Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 37 Asia Pacific Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 38 Asia Pacific Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

Table 40 The Middle East & Africa Sex Cord–Gonadal Stromal Tumor Market, By Tumor Type, 2020–2027, (USD Million)

Table 41 The Middle East & Africa Sex Cord–Gonadal Stromal Tumor Market, By Diagnosis, 2020–2027, (USD Million)

Table 42 The Middle East & Africa Sex Cord–Gonadal Stromal Tumor Market, By Treatment, 2020–2027, (USD Million)

Table 43 The Middle East & Africa Sex Cord–Gonadal Stromal Tumor Market, By End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Sex Cord–Gonadal Stromal Tumor Market

Figure 3 Segmentation Market Dynamics For Sex Cord–Gonadal Stromal Tumor Market

Figure 4 Global Sex Cord–Gonadal Stromal Tumor Market Share, By Tumor Type 2020

Figure 5 Global Sex Cord–Gonadal Stromal Tumor Market Share, By Diagnosis 2020

Figure 6 Global Sex Cord–Gonadal Stromal Tumor Market Share, By Treatment 2020

Figure 7 Global Sex Cord–Gonadal Stromal Tumor Market Share, By End-User 2020

Figure 8 Global Sex Cord–Gonadal Stromal Tumor Market Share, By Region, 2020

Figure 9 North America Sex Cord–Gonadal Stromal Tumor Market Share, By Country, 2020

Figure 10 Europe Sex Cord–Gonadal Stromal Tumor Market Share, By Country, 2020

Figure 11 Asia Pacific Sex Cord–Gonadal Stromal Tumor Market Share, By Country, 2020

Figure 12 Middle East & Africa Sex Cord–Gonadal Stromal Tumor Market Share, By Country, 2020

Figure 13 Global Sex Cord–Gonadal Stromal Tumor Market: Company Share Analysis, 2020 (%)

Figure 14 Abbott: Key Financials

Figure 15 Abbott: Segmental Revenue

Figure 16 Abbott: Geographical Revenue

Figure 17 Beckman, Dickinson And Company (BD): Key Financials

Figure 18 Beckman, Dickinson And Company (BD): Segmental Revenue

Figure 19 Beckman, Dickinson And Company (BD): Geographical Revenue

Figure 20 Johnson & Johnson Services, Inc.: Key Financials

Figure 21 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 22 Johnson & Johnson Services, Inc.: Geographical Revenue

Figure 23 Bio-Rad Laboratories, Inc.: Key Financials

Figure 24 Bio-Rad Laboratories, Inc.: Segmental Revenue

Figure 25 Bio-Rad Laboratories, Inc.: Geographical Revenue

Figure 26 BOSTON SCIENTIFIC CORPORATION: Key Financials

Figure 27 BOSTON SCIENTIFIC CORPORATION: Segmental Revenue

Figure 28 BOSTON SCIENTIFIC CORPORATION Geographical Revenue

Figure 29 CooperSurgical Inc.: Key Financials

Figure 30 CooperSurgical Inc.: Segmental Revenue

Figure 31 CooperSurgical Inc.: Geographical Revenue

Figure 32 DANAHER CORPORATION: Key Financials

Figure 33 DANAHER CORPORATION: Segmental Revenue

Figure 34 DANAHER CORPORATION: Geographical Revenue